<DOC>
	<DOCNO>NCT01321463</DOCNO>
	<brief_summary>PH-797804 oral ant-inflammatory drug may reduce inflammation associate COPD . PH-797804 dose patient COPD evaluate potential safety efficacy profile COPD .</brief_summary>
	<brief_title>Study To Evaluate The Efficacy And Safety Of PH-797804 For 12 Weeks In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease ( COPD ) Taking Salmeterol Xinafoate/Fluticasone Propionate Combination</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>Male female subject , include , age 40 80 year . Subjects diagnosis , least 6 month , moderate severe COPD ( GOLD ) meet criterion Stage IIIII disease . Subjects must smoke history least 10 packyears current smoker exsmokers give &gt; 6 month ago . Subjects must treat LABA/ICS combination least 1 month prior screen . A COPD exacerbation require treatment oral steroid hospitalization treatment COPD within 3 month screen . History presence significant cardiovascular disease . ECG abnormality . Significant concomitant clinical disease could interfere conduct , safety interpretation result study . Evidence organ blood disorder .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>